CELU vs. LTRN, EGRX, MURA, IMMX, HCWB, EQ, KZR, MNOV, RLYB, and SCYX
Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Lantern Pharma (LTRN), Eagle Pharmaceuticals (EGRX), Mural Oncology (MURA), Immix Biopharma (IMMX), HCW Biologics (HCWB), Equillium (EQ), Kezar Life Sciences (KZR), MediciNova (MNOV), Rallybio (RLYB), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical preparations" industry.
Lantern Pharma (NASDAQ:LTRN) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment.
Lantern Pharma received 4 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 75.00% of users gave Lantern Pharma an outperform vote while only 42.11% of users gave Celularity an outperform vote.
Celularity has higher revenue and earnings than Lantern Pharma.
Lantern Pharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
In the previous week, Lantern Pharma had 3 more articles in the media than Celularity. MarketBeat recorded 6 mentions for Lantern Pharma and 3 mentions for Celularity. Celularity's average media sentiment score of -0.05 beat Lantern Pharma's score of -0.20 indicating that Lantern Pharma is being referred to more favorably in the media.
28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 6.9% of Lantern Pharma shares are owned by insiders. Comparatively, 20.7% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Lantern Pharma has a net margin of 0.00% compared to Lantern Pharma's net margin of -1,226.72%. Lantern Pharma's return on equity of 30.79% beat Celularity's return on equity.
Summary
Lantern Pharma beats Celularity on 7 of the 12 factors compared between the two stocks.
Get Celularity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celularity Competitors List
Related Companies and Tools
